Bettina Broughton
Acute Care · Rochester, NYNPI 1831401314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,509 of the $7,417 with a category attached, or 74.3%. 30 manufacturers reported payments, led by Procept Biorobotics Corporation at 45.1% of the total. Among acute care clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $43.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$3K
- Sumitomo Pharma America, Inc.$566
- Astellas Pharma US Inc$431
- Johnson & Johnson$407
- Olympus America Inc.$287
- EDAP Technomed Inc$277
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,84325%
- Food & beverage$5,50974%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 26 | $3,343 |
| Sumitomo Pharma America, Inc. | 41 | $566 |
| Astellas Pharma US Inc | 22 | $431 |
| Johnson & Johnson(2 entities) | 11 | $407 |
| Olympus America Inc. | 4 | $287 |
| EDAP Technomed Inc | 2 | $277 |
| AbbVie | 8 | $187 |
| Urovant Sciences Inc | 6 | $185 |
| Biotissue Holdings Inc. | 8 | $178 |
| Medtronic | 4 | $166 |
| Pfizer | 9 | $152 |
| Antares Pharma, Inc. | 4 | $152 |
| Myriad Genetic Laboratories, Inc. | 2 | $138 |
| Sanofi | 1 | $122 |
| Coloplast | 3 | $122 |
| Myovant Sciences Inc. | 1 | $109 |
| Tolmar, Inc. | 1 | $94 |
| Calyxo, Inc. | 1 | $92 |
| Dentsply IH AB | 2 | $79 |
| Endo USA, Inc. | 3 | $66 |
| Axonics, Inc. | 2 | $48 |
| Urogen Pharma, Inc. | 2 | $38 |
| Telix Pharmaceuticals | 2 | $34 |
| Merck | 1 | $28 |
| Baxter Healthcare | 1 | $27 |
| Teleflex LLC | 1 | $25 |
| Blue Earth Diagnostics | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $21 |
| Boston Scientific | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$2,832
- iTIND System$255
- GEMTESA$221
- AQUABEAM SYSTEM$170
- myRisk$117
- ORGOVYX$109
- VISTASEAL$104
- XTANDI$102
How this compares
$7,417 in reported general payments places this provider in the 95th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 143 | $112,079 |
| GemtesaVibegron | 104 | $88,123 |
| Mirabegron ErMirabegron | 48 | $23,212 |
| Tamsulosin Hcl | 637 | $10,493 |
| Finasteride | 402 | $6,257 |
| Tadalafil | 12 | $5,490 |
| Trospium Chloride | 70 | $3,966 |
| Trospium Chloride ErTrospium Chloride | 27 | $3,422 |
| Silodosin | 24 | $2,700 |
| Dutasteride | 37 | $1,830 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 90 | $1,825 |
| Solifenacin Succinate | 40 | $1,524 |
| Estradiol | 21 | $1,210 |
| Desmopressin Acetate | 14 | $780 |
| Cephalexin | 21 | $366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $431 | $112,079143 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $566 | $88,123104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 980 acute care providers in New York.
Other acute care in Rochester
- Ann FrickeRochester$6K
- Marie BianchiRochester$3K
- Daniel VerinaNew York$464K
- Michele BiscossiSaratoga Springs$64K
- Heidi YipCanandaigua$29K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Ann HarrisBrooklyn$14K
- Marcel RozarioMedina$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.